Current Report Filing (8-k)

Date : 12/30/2019 @ 10:14PM
Source : Edgar (US Regulatory)
Stock : Johnson and Johnson (JNJ)
Quote : 139.76  0.0 (0.00%) @ 11:34AM
Pre-Market
Last Trade
Last $ 142.44 ▲ 2.68 (1.92%)

Current Report Filing (8-k)

false0000200406 0000200406 2019-12-30 2019-12-30 0000200406 jnj:A0.650NotesDue2024Member 2019-12-30 2019-12-30 0000200406 jnj:A1.650NotesDue2035Member 2019-12-30 2019-12-30 0000200406 us-gaap:CommonStockMember 2019-12-30 2019-12-30 0000200406 jnj:A1.150NotesDue2028Member 2019-12-30 2019-12-30 0000200406 jnj:A0.250NotesDue2022Member 2019-12-30 2019-12-30 0000200406 jnj:A5.50NotesDue2024Member 2019-12-30 2019-12-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
December 30, 2019
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey
1-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
0.250% Notes Due January 2022
JNJ
New York Stock Exchange
0.650% Notes Due May 2024
JNJ
New York Stock Exchange
5.50% Notes Due November 2024
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ
New York Stock Exchange
1.650% Notes Due May 2035
JNJ
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 






Item 8.01    Other Events.

On December 30, 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for $750 million. Should Janssen pursue bermekimab indications outside of dermatology, XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. Janssen Research & Development, LLC will develop bermekimab. The agreement was executed through Janssen Biotech, Inc.

The related press release announcing the acquisition is attached to this Report as Exhibit 99.1.

 
Item 9.01. Exhibits

(d)     Exhibits. 
 
Exhibit No.
 
Description of Exhibit
 
 
Johnson & Johnson Press Release dated December 30, 2019.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 (Registrant)
 
 
 
 
Date: 
December 30, 2019
By:
/s/ Renee A. Brutus
 
 
 
 
Renee A. Brutus
Assistant Secretary
 



Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Intraday Stock Chart

Today : Tuesday 7 April 2020

Click Here for more Johnson and Johnson Charts.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.